Interactions Between Striatum and Cerebellum in ADCY5 and PRRT2 Dystonias

NCT ID: NCT03481491

Last Updated: 2025-11-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

104 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-06

Study Completion Date

2024-08-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators will study the relationship between the basal ganglia and the cerebellum in dystonia by associating cerebellar stimulations with functional magnetic resonance imaging analysis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Although dysfunctions in both basal ganglia and cerebellum in dystonia are well documented, the functional relationships between these two important motor control networks remains unclear in the context of dystonia. Here the investigators propose to tackle this issue by associating cerebellar stimulations with functional analysis using fMRI in dystonic patients.

The working hypothesis is that the primary torsion dystonia (PTD) pathophysiology involves dysfunction of striatum that is amplified by dysregulation of the cerebello-thalamo-striatal pathway.

The project is to study dystonia forms resulting primarily from dysfunctions of the striatum (patients with mutation of the ADCY5 gene) and compare them with patients with putative dysfunction of the cerebellum (patients with mutation of the PRRT2 gene) and healthy controls. In these patients, the investigators will look for (1) how cerebello-thalamo striatal pathway can be influenced by striatal dysfunctions and (2) whether cerebellar stimulation may prevent (or worsen?) the disrupted activity in the basal ganglia and (3) whether striatum-related dystonia share the same abnormal network with another form of dystonia resulting from another dysfunction (patients with PRRT2 mutation).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dystonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants
Participants will be blinded to the TMS procedure (SHAM or real stimulation).

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sham cerebellar stimulation

Participants will receive a Sham stimulation (inefficient probe) applied over the cerebellum.

Group Type SHAM_COMPARATOR

transcranial magnetic stimulation of the cerebellum

Intervention Type OTHER

The intervention will consist in a continuous theta burst stimulation of the cerebellum under neuronavigation.

Real cerebellar stimulation

Participants will receive a real continuous theta burst stimulation (cTBS) applied over the cerebellum.

Group Type ACTIVE_COMPARATOR

transcranial magnetic stimulation of the cerebellum

Intervention Type OTHER

The intervention will consist in a continuous theta burst stimulation of the cerebellum under neuronavigation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

transcranial magnetic stimulation of the cerebellum

The intervention will consist in a continuous theta burst stimulation of the cerebellum under neuronavigation.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* clinical diagnosis of Dystonia
* characterized ADCY5 or PRRT2 mutation
* must have a European Social Security card or a parent having an European Social Security card
* must be older than \> 15 years 3 months
* must be able to give informed consent or, for minor patients, parents must be able to give informed consent
* must be able to comply with all study procedures, based on the judgment by the investigator(s).

Exclusion Criteria

* major depression or any major mental disorders (axis I disorders)
* neurologic disorder other than dystonia
* presence of pacemaker, intracardiac lines, implanted pumps or stimulators, or metal objects inside the eye or skull, cochlear implant
* Permanent makeup of lips or eyelids
* Black large tattoo close to the head
* Severe claustrophobia
* Current pregnancy or breast feeding
* Open scalp wounds or scalp infection,
* epilepsy or seizures
* Taking at the time of the study: ketamine, antidepressants, ganciclovir, ritonavir, amphetamines, antiemetic.
Minimum Eligible Age

15 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Emmanuel Flamand-Roze, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Pitié-Salpêtrière

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Département de Neurologie, Fédération des Maladies du Système Nerveux, GH Pitié-Salpêtrière, 47 Bd de l'Hôpital

Paris, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Ekmen A, Meneret A, Valabregue R, Beranger B, Worbe Y, Lamy JC, Mehdi S, Herve A, Adanyeguh I, Temiz G, Damier P, Gras D, Roubertie A, Piard J, Navarro V, Mutez E, Riant F, Welniarz Q, Vidailhet M, Lehericy S, Meunier S, Gallea C, Roze E. Cerebellum Dysfunction in Patients With PRRT2-Related Paroxysmal Dyskinesia. Neurology. 2022 Mar 8;98(10):e1077-e1089. doi: 10.1212/WNL.0000000000200060. Epub 2022 Jan 20.

Reference Type RESULT
PMID: 35058336 (View on PubMed)

Ekmen A, Doulazmi M, Meneret A, Jegatheesan P, Herve A, Damier P, Gras D, Roubertie A, Piard J, Mutez E, Tarrano C, Welniarz Q, Vidailhet M, Worbe Y, Gallea C, Roze E. Non-Motor Symptoms and Quality of Life in Patients with PRRT2-Related Paroxysmal Kinesigenic Dyskinesia. Mov Disord Clin Pract. 2023 Jun 5;10(7):1082-1089. doi: 10.1002/mdc3.13795. eCollection 2023 Jul.

Reference Type RESULT
PMID: 37476308 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017-A01843-50

Identifier Type: REGISTRY

Identifier Source: secondary_id

C16-128

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Brain Anatomy in Dystonia
NCT00031369 TERMINATED
rTMS and Retraining in Focal Hand Dystonia
NCT01738581 COMPLETED PHASE1/PHASE2